Offering enhanced bioavailability and reduction of adverse events with proprietary ARx systems
ARx custom formulates and manufactures drug-loaded mucosal film systems, designed to bond to challenging mucosal tissues for specified periods of time, while allowing the active pharmaceutical ingredient to permeate the mucosal tissue and proving comfortable for the patient. The systems may be single- or multi-layer and formulated for removal upon treatment, or to completely erode at a predetermined time. ARx formulates multi-layer systems for the added benefit of ensuring active pharmaceutical ingredient penetration through mucosal tissue before the entire system is dissolved.
By allowing the drug to permeate before dissolving, buccal thin films increase bioavailability and reduce adverse events and metabolites associated with the first pass metabolism. This results in an enhanced patient experience and a safer drug product.
Benefits of ARx buccal thin film delivery systems for your drug, your patient, and your brand:
| Your Drug | Your Patient | Your Brand |
|---|---|---|
| Enhanced bioavailability through elimination of the 1st pass effect | Improved adverse event profile associated with avoidance of 1st pass metabolism | Market success through enhanced patient compliance |
| Tailored drug release or dissolution in a specific fluid or pH | Comfortable and discreet during dosing | Improvement over traditional dosage forms with life-cycle management opportunities |
| GRAS excipients utilized to reduce regulatory risk | Eliminates the need to swallow medication | Customized size, shape, thickness, and color for brand recognition |
| Optimal stability and API compatibility with single or multi-layer systems | Easy to transport and administer | Individually pouched units offer additional space for printing logos and brand names |